premix insulin — Competitive Intelligence Brief

premix insulin (premix insulin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin combination product. Area: Diabetes.

marketed Insulin combination product Insulin receptor Diabetes Small molecule

Target snapshot

premix insulin (premix insulin) — Shanghai 6th People's Hospital. Premix insulin is a combination of rapid-acting and intermediate-acting insulin that replaces or supplements the body's natural insulin to regulate blood glucose levels.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
premix insulin TARGET	premix insulin	Shanghai 6th People's Hospital	marketed	Insulin combination product	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin combination product class)

1. Eli Lilly and Company · 3 drugs in this class
2. Biodel · 1 drug in this class
3. Shanghai 6th People's Hospital · 1 drug in this class